AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02760277 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vamorolone 0.25 mg/day/day
Description: Oral administration of 0.25 mg/kg/day daily for 24 weeks.
Study NCT02760277 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vamorolone 0.75 mg/day/day
Description: Oral administration of 0.75 mg/kg/day daily for 24 weeks.
Study NCT02760277 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vamorolone 2.0 mg/day/day
Description: Oral administration of 2.0 mg/kg/day daily for 24 weeks.
Study NCT02760277 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vamorolone 6.0 mg/day/day
Description: Oral administration of 6.0 mg/kg/day daily for 24 weeks.
Study NCT02880540 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl
Study NCT02880540 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine
Study NCT02880540 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Study NCT04518605 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Low protein breakfast
Description: Low protein yoghurt containing approx. 2 g protein per 100 g. Participants will be asked to consume \~60 g bread, 20 g jam and 250 ml juice for breakfast.
Study NCT04518605 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: High protein breakfast
Description: High protein yoghurt containing approx. 10 g protein per 100 g. Participants will be asked to consume 300 g (=3 dl) yoghurt with 40 g oats for breakfast.
Study NCT04518605 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise training
Description: Participants will be asked to participate in organized exercise training 3 times per week.
Study NCT02031549 — intervention group
Intervention type: OTHER
Intervention: SpermComet assay
Description: Measurement of DNA fragmentation in samples of surplus sperm (diagnostic, not an intervention).
Study NCT01026493 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide 150 mg x 5 days
Description: 150 mg/m2 x 5 days (up to 200 mg/m2 after 2nd cycle)\*, with a 28-day cycle; dose reduction to 125 mg/m2 if necessary. Treatment continues until progressive disease unless toxicity or the discretion of the treating physician preclude
Study NCT01412762 — intervention group
Intervention type: BEHAVIORAL
Intervention: patient interviews
Description: The pre-operative interview will be within 4 weeks of planned surgery and the postoperative interview within 8 weeks of surgery completion. This initial study is designed to develop an instrument to measure patient preoperative expectations in this patient population.
Study NCT01412762 — intervention group
Intervention type: BEHAVIORAL
Intervention: CITSAV survey
Description: Individual semi-structured qualitative interviews will be conducted with a total of 10 patients and 5 clinicians during this phase to identify and discuss levels of satisfaction, level of burden, potential obstacles to implementation, as well as suggestions for improving the intervention
Study NCT01026493 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-888 40 mg x 5 days
Description: 40 mg bid x 5 days/28-day cycle. Treatment continues until progressive disease unless toxicity or the discretion of the treating physician preclude
Study NCT02879214 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Simultaneous boost along with chemo
Description: Prior studies have utilized a sequential boost to deliver a total dose of 55 - 60 Gy to the pelvic sidewall (covering the lower pelvic lymph nodes), including 8-10 Gy that is usually delivered with brachytherapy (1-3), the studies often use single drug. This study treatment plan will use dose intensify in both chemotherapy and radiation. The chemotherapy have two drugs regimens of mitomycin with cisplatin or taxol with cisplatin along of radiation dose escalate, the RT dose escalation to biological GTV defined by PET scan to dose of 57.50 Gy in 25 fx while the elective volumes are held constant at 45 Gy.
Study NCT02597413 — intervention group
Intervention type: PROCEDURE
Intervention: Catheterization
Description: Women in this group will be systematically catheterized before leaving the delivery room.
Study NCT01515839 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Multivitamin Supplement intervention
Description: We recommend the following protocol:~1. 2 tablets of a high quality multivitamin BID~2. 2 capsules of omega 3 fish oil BID for a total of 3 grams daily~3. 3 capsules of a brain and memory formula BID which contains Acetyl-L-Carnitine (HCL) 1000 mg, Ginkgo Biloba Extract 120 mg, Alpha-Lipoic Acid (ALA) 300 mg, Huperzine A (Huperzia serrata)150 mcg, N-Acetyl-L-Cysteine (NAC) 600mg, Phosphatidyl Serine (soy) 100 mg, Vinpocetine 15mg~4. Weight loss
Study NCT01841372 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Second Life
Description: Second Life is an online virtual reality environment.
Study NCT01841372 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Group Phone Conference Call
Study NCT00505921 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Campath-1H
Description: 3 mg through the catheter Day 1 then 10 mg on Day 2, and 30 mg on Days 3 and 10 of chemotherapy treatment.
Study NCT00505921 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: G-CSF
Description: 10 mg/kg subcutaneously (sc) on day +5 (in a.m.) for Stem Cell Mobilization.
Study NCT00505921 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GM-CSF
Description: 250 m/m2 subcutaneously (sc) on Day +5 (in p.m.) for Stem Cell Mobilization.
Study NCT00505921 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BCNU
Description: 300 mg/m2 IV over 1 hour on day -6
Study NCT00505921 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Stem Cell Transplant
Description: Stem cell infusion on Day 0.
Study NCT00505921 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Preparative Regimen for Allogenic Stem Cell Transplantation
Description: Campath 15mg/day (days -6 to -4), fludarabine 30 mg/m2 IV/day (days -6 to -4) and cyclophosphamide 750 mg/m2 IV/day (1000 mg/m2 IV/day if unrelated) (days -6 to -4). Low dose total body irradiation of 2 Gy on day 0.
Study NCT00505921 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: 200 mg/m2 IV twice a day on day -5 through -2 (total 8 doses),
Study NCT00505921 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: 200 mg/m2 IV twice on day -5 to -2 (total 8 doses)
Study NCT00505921 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan
Description: 140 mg/m2 IV on day -1.
Study NCT00505921 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Campath
Description: 15 mg/day (days -6 to -4) for preparative regimen Allogenic Stem Cell Transplantation
Study NCT00505921 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: 30 mg/m2 IV/day (days -6 to -4)
Study NCT00505921 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 750 mg/m2 IV/day (1000 mg/m2 IV/day if unrelated) (days -6 to -4).
Study NCT00505921 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Low dose total body irradiation
Description: Low dose total body irradiation of 2 Gy day 0.
Study NCT01458626 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: mirtazapine
Description: mirtazapine 30mg QD
Study NCT01458626 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: paroxetine 20mg QD
Description: paroxetine 20mg QD
Study NCT00772837 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omeprazole + Clarithromycin + Amoxycillin
Description: Omeprazole 20mg BID for 1 week along with Clarithromycin 500mg BD and Amoxycillin 1g BD for 1 week
Study NCT00772837 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Omeprazole + placebo antibiotics
Description: omeprazole 20 mg bid for 1 week along with placebo antibiotics for 1 week
Study NCT04053582 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: AMT
Description: The session will be done on an individual basis. AMT group will receive neurofeedback training from the PCC while focusing on the physical sensations of the breath. The session will last one hour, including 3 neurofeedback runs during which subjects will undergo three conditions across three consecutive blocks: Rest (30s), Describe (view an adjective and decide whether the word describes them; 20s), and Focus on the Breath with neurofeedback (70s).
Study NCT04053582 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Sham
Description: The session will be done on an individual basis. Sham group will receive artificial neurofeedback while focusing on the physical sensations of the breath. The session will last one hour, including 3 sham neurofeedback runs during which subjects will undergo three conditions across three consecutive blocks: Rest (30s), Describe (view an adjective and decide whether the word describes them; 20s), and Focus on the Breath with artificial neurofeedback (70s).
Study NCT05677399 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: aquatic exercise and peloidotherapy
Description: Treatment group received 30 minutes of aquatic exercise by a physiotherapist in a warmed up to 33° C tap water and 30 minutes of mud pack treatment at 42°C on both knees 5 weekdays for 2 consecutive weeks (totally 10 sessions).
Study NCT03352284 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Straumann Pure Ceramic Implant
Description: The surgical technique begins with the lift of a vestibular mucoperiosteal flap respecting the papillae of the adjacent teeth. After the alveolar bone is exposed, the sequence of drilling and placement of the intra-bone fixation are carried out. In case of fenestrations or dehiscence, they are treated by xenograft and collagen-absorbable membrane. Once the implant is placed, a healing cap or provisional prosthesis is placed depending on the torque achieved. Finally, the flap is replaced and sutured.
Study NCT02978469 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Life style changing: reducing sedentary behavior
Description: The program includes 23 meetings held once per week (with holiday breaks). Each meeting lasts 90 minutes, consisting of exercise training.~the group will meet for information providing and discussion. Participants are guided in the process of creating a focussed individualized activity plan.~In the group setting they will experience a variety of activities enabling them to explore activities they prefer: each participant receive three personal consultation meetings. The group will experience sport and recreational activities with persons with physical impairments. Also activities in sport in community facilities.
Study NCT02978469 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Life style changing: reducing sedentary behavior
Description: The program includes 23 meetings held once per week (with holiday breaks). Each meeting lasts 90 minutes, consisting of exercise training.~the group will meet for information providing and discussion. Participants are guided in the process of creating a focussed individualized activity plan.~In the group setting they will experience a variety of activities enabling them to explore activities they prefer: each participant receive three personal consultation meetings. The group will experience sport and recreational activities with persons with physical impairments. Also activities in sport in community facilities.
Study NCT01849614 — intervention group
Intervention type: OTHER
Intervention: Cardiac SPECT perfusion scan
Description: A SPECT cardiac perfusion scan provides a three-dimensional map of blood flow to the heart tissue. The scan will be taken at rest only.
Study NCT02667639 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: RPH-104
Description: Anti-IL-1 Mab
Study NCT02667639 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Sodium chloride Sterile Injection 0.9% w/v
Description: Sterile saline solution
Study NCT03777241 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Behavioral Intervention Team
Description: Multidisciplinary team to assist with actively identifying and managing mental illness and substance abuse disorders at their earliest possible time during hospitalization.
Study NCT05623176 — intervention group
Intervention type: OTHER
Intervention: Standardised laparotomy care
Description: This is a cohort study and no intervention as part of the study has been introduced. We are studying two groups and comparing the two before and after the introduction of a standardised laparotomy care protocol as part of a clinical quality improvement measure.
Study NCT00386282 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: mifepristone-misoprostol treatment
Description: 200 mg mifepristone followed by 800 mcg buccal misoprostol 24-48 hours after the mifepristone.
Study NCT04695912 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: The SENS motion® sensor
Description: The sensor is a wearable physical tracker giving investigators feedback about daily activity~The SENS motion® system consists of:~The sensor 'SENS Motion Patch' A smart-phone application 'SENS motion´~SENS motion cloud storage database, a web-based visualization of data for the healthcare team~The iSpine app shows activity-information recorded by the sensor to the patient and gives nudges to activity.
Study NCT00976872 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: omega-3
Description: omega-3: 2 pills of Omega950®, Solgar, New Jersey, USA. Each pill contained 542mg of eicosapentaenoic acid, EPA, and 405mg of docosahexanoic acid, DHA
Study NCT00976872 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: hard gelatin capsule of Capsugel®, France, filled with 1ml of soya oil
Study NCT03777241 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care
Description: Participants in this group will receive standard of care.
Study NCT03567096 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: BiV pacing with MPP and SyncAV
Description: This cohort will receive Bi-Ventricular Pacing (left ventricle and right ventricle pacing) with MultiPoint Pacing of the left ventricle (two stimulation sites) and the SyncAV algorithm active.
Study NCT02398240 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: Days: 1 and 15 Dose: 25 mg/m2/dose.
Study NCT02398240 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: Days: 1 and 15 Dose: 1.5 mg/m2/dose (max: 2 mg/dose).
Study NCT02398240 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Days: 2 and 16 Dose: 375 mg/m2/dose.
Study NCT00984308 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: CPAP Therapy for Newly Diagnosed Obstructive Sleep Apnea (OSA)
Description: Continuous Positive Airway Pressure (CPAP) is provided for those patients who are diagnosed with OSA.
Study NCT00984308 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: CPAP Therapy for Newly Diagnosed Obstructive Sleep Apnea (OSA)
Description: Continuous Positive Airway Pressure (CPAP) is provided for those patients who are diagnosed with OSA.
Study NCT06173583 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Detection/screening
Description: Using ARISCAT and LAS VEGUS risk scores for predicting PPCs
Study NCT03697642 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: With nasopharyngeal airway
Description: Nasopharyngeal airway is previously inserted into selected nostril. NG tube is properly lubricated and placed through Nasopharyngeal airway.
Study NCT03697642 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Without nasopharyngeal airway
Description: NG tube is properly lubricated and placed into selected nostril
Study NCT02405156 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole
Study NCT02405156 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02405156 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Misoprostol
Study NCT02405156 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Misoprostol
Study NCT01620229 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: brentuximab vedotin
Description: Given IV
Study NCT01620229 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT01620229 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies
Study NCT04486651 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan Hydrochloride Injection
Description: 160 mg/m² administered as IV infusion on Day 1 of each 14-day cycle.
Study NCT04486651 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Irinotecan Hydrochloride Injection
Description: 160 mg/m² administered as IV infusion on Day 1 of each 14-day cycle.
Study NCT04486651 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HX008
Description: 200 mg administered as IV infusion on Day 1 of each 21-day cycle.
Study NCT04486651 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered as IV infusion on Day 1 of each 21-day cycle.
Study NCT02413853 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CBP/beta-catenin Antagonist PRI-724
Description: Given IV
Study NCT02413853 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Given IV
Study NCT02413853 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin Calcium
Description: Given IV
Study NCT02413853 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Given IV
Study NCT02413853 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorouracil
Description: Given IV
Study NCT02413853 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT02799264 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabotegravir 30 mg
Description: Cabotegravir (GSK1265744B ) is available as white to almost white, oval shaped, film coated tablet, of weight 515 mg. The tablet contains micronized cabotegravir, lactose monohydrate, microcrystalline cellulose, hypromellose, sodium starch glycolate, and magnesium stearate. Each tablet is equivalent to 30 mg cabotegravir and needs to be taken orally with 240 mL of water. Cabotegravir tablet will be administered to subjects either in fasting condition or following a high fat meal.
Study NCT02468219 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: cardiovascular rehabilitation program
Description: Phase I: 2-weeks of respiratory muscle training and neuromuscular electrical stimulation (daily at hospital).~Phase II: 6-weeks of respiratory muscle training and neuromuscular electrical stimulation (daily at home).~Phase III: 8-weeks of supervised, structured, combined aerobic and resistance training.
Study NCT02468219 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: cardiovascular rehabilitation program
Description: Phase I: 2-weeks of respiratory muscle training and neuromuscular electrical stimulation (daily at hospital).~Phase II: 6-weeks of respiratory muscle training and neuromuscular electrical stimulation (daily at home).~Phase III: 8-weeks of supervised, structured, combined aerobic and resistance training.
Study NCT04554524 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy+Pembrolizumab.
Description: Eligible subjects will receive 4 cycles carbo-paclitaxel/ nab-paclitaxel combined with pembrolizumab. Response rate assessed by the site investigators according to the Response Evaluation Criteria In Solid Tumors (RECIST v1.1). After 4 cycles treatment, complete response subjects continue carbo-paclitaxel/ nab-paclitaxel combined with pembrolizumab up to disease progression, some of partial disease and stable disease subjects can receive surgical treatment. And then continue carbo-paclitaxel/ nab-paclitaxel combined with pembrolizumab up to disease progression, other partial disease and stable disease subjects cannot be removed by surgery will continue carbo-paclitaxel/ nab-paclitaxel combined with pembrolizumab for 4 cycles and then pembrolizumab or Normal Saline up to disease progression.
Study NCT01948700 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Motivational Interviewing
Study NCT01948700 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Education
Study NCT04187807 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melatonin 5 mg
Description: Placebo
Study NCT04187807 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Melatonin 5 mg
Description: Placebo
Study NCT00223639 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Topiramate
Description: 200mg twice a day
Study NCT00223639 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topiramate
Description: 200mg twice a day
Study NCT00544310 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Anti adhesion agent
Description: Adhesions prevention
Study NCT04312334 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Control
Description: Soap: Non-antimicrobial bar soap will be used as a reference product for four of the the experiments. Hand-cleaning with SuperTowel will be the reference produce for two of the experiments.
Study NCT03567096 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LV only pacing with MPP and SyncAV
Description: This cohort will receive left ventricular only pacing (no right ventricle pacing) with MultiPoint Pacing of the left ventricle (two stimulation sites) and the SyncAV algorithm active.